{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:55:21Z","timestamp":1795056921721,"version":"4.10.2"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101158172"],"award-info":[{"award-number":["101158172"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101100859"],"award-info":[{"award-number":["101100859"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["LA 3680\/9-1"],"award-info":[{"award-number":["LA 3680\/9-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["390874280"],"award-info":[{"award-number":["390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2155"],"award-info":[{"award-number":["EXC 2155"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["10-1"],"award-info":[{"award-number":["10-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010564","name":"Deutsches Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["852178"],"award-info":[{"award-number":["852178"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030859","name":"REBIRTH HANNOVER Forschungszentrum f\u00fcr translationale regenerative Medizin","doi-asserted-by":"publisher","award":["ZN3340"],"award-info":[{"award-number":["ZN3340"]}],"id":[{"id":"10.13039\/100030859","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.addr.2025.115713","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T23:37:45Z","timestamp":1760398665000},"page":"115713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches"],"prefix":"10.1016","volume":"227","author":[{"given":"D\u00e9bora","family":"Bas\u00edlio-Queir\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoukje J.C.","family":"van der Stegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.addr.2025.115713_bb0005","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2012.11.003","article-title":"T lymphocyte potential Marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures","volume":"2","author":"Kennedy","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2025.115713_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.4258","article-title":"Progenitor t-cell differentiation from hematopoietic stem cells using delta-like-4 and VcAm-1","author":"Shukla","year":"2017","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.addr.2025.115713_bb0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.stem.2018.12.011","article-title":"Organoid-induced differentiation of conventional T cells from human pluripotent stem cells","volume":"24","author":"Montel-Hagen","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.stemcr.2015.01.005","article-title":"Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies","volume":"4","author":"Lachmann","year":"2015","journal-title":"Stem Cell Reports"},{"issue":"9","key":"10.1016\/j.addr.2025.115713_bb0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nbt.1562","article-title":"Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases","volume":"27","author":"Hockemeyer","year":"2009","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.addr.2025.115713_bb0030","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/stem.2115","article-title":"In vitro T-cell generation from adult, embryonic, and induced pluripotent stem cells: many roads to one destination","volume":"33","author":"Smith","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.addr.2025.115713_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.640703","article-title":"Macrophages derived from human induced pluripotent stem cells: the diversity of protocols, future prospects, and outstanding questions","volume":"9","author":"Lyadova","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular adjuvant properties, direct cytotoxicity of re-differentiated V\u03b124 invariant NKT-like cells from human induced pluripotent stem cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.addr.2025.115713_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/stem.2465","article-title":"Efficient regeneration of human V24+ invariant natural killer T cells and their anti-tumor activity in vivo efficient regeneration of human Va24 1 invariant natural killer T cells and their anti-tumor activity in vivo","author":"Yamada","year":"2016","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.addr.2025.115713_bb0050","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.stem.2013.03.001","article-title":"Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and Redifferentiation","volume":"12","author":"Wakao","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.addr.2025.115713_bb0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.stemcr.2023.02.010","article-title":"Re-generation of cytotoxic \u03b3\u03b4T cells with distinctive signatures from human \u03b3\u03b4T-derived iPSCs","volume":"18","author":"Murai","year":"2023","journal-title":"Stem Cell Reports"},{"issue":"11","key":"10.1016\/j.addr.2025.115713_bb0060","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","article-title":"Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T cells from T cell-derived induced pluripotent stem cells HHS public access author manuscript","volume":"6","author":"van der Stegen","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2025.115713_bb0065","series-title":"DLL4 and VCAM1 Enhance the Emergence of T Cell-Competent Hematopoietic Progenitors from Human Pluripotent Stem Cells","author":"Michaels","year":"2022"},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0070","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.stem.2022.06.014","article-title":"EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity","volume":"29","author":"Jing","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25245-8","article-title":"DL4-\u03bcbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system","volume":"12","author":"Trotman-Grant","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.addr.2025.115713_bb0085","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-16-1149","article-title":"Regeneration of CD8\u03b1\u03b2 T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity","volume":"76","author":"Maeda","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115713_bb0090","article-title":"Polarization of human iPSC-derived macrophages directs their immunological response to secondary pro-inflammatory stimuli","volume":"17","author":"Schinke","year":"2022","journal-title":"J Immunol Regen Med"},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0095","article-title":"Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions","volume":"8","author":"van Wilgenburg","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.addr.2025.115713_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01016","article-title":"Macrophages derived from human induced pluripotent stem cells are low-activated \u2018na\u00efve-like\u2019 cells capable of restricting mycobacteria growth","volume":"11","author":"Nenasheva","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07570-7","article-title":"Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections","volume":"9","author":"Ackermann","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115713_bb0110","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4939-7837-3_2","article-title":"A simple multistep protocol for differentiating human induced pluripotent stem cells into functional macrophages","volume":"vol. 1784","author":"Mukherjee","year":"2018"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.addr.2025.115713_bb0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115713_bb0125","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","author":"Majzner","year":"2019","journal-title":"Nat. Publ. Group"},{"key":"10.1016\/j.addr.2025.115713_bb0130","article-title":"Macrophage biology in development, homeostasis and disease","volume":"25","author":"Wynn","year":"2013"},{"key":"10.1016\/j.addr.2025.115713_bb0135","article-title":"High cost of chimeric antigen receptor T-cells","volume":"43","author":"Scheffer Cliff","year":"2023","journal-title":"Challenges Solutions"},{"issue":"5","key":"10.1016\/j.addr.2025.115713_bb0140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.addr.2025.115713_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1139482","article-title":"Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115713_bb0150","article-title":"Addressing patient to patient variability for autologous CAR T therapies","author":"Jiang","year":"2021","journal-title":"Elsevier B.V."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.addr.2025.115713_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2024.104648","article-title":"The pluripotent path to immunotherapy","volume":"139","author":"Diop","year":"2024","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/j.addr.2025.115713_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002595","article-title":"Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing","volume":"9","author":"Lu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2025.115713_bb0170","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis","author":"Mart\u00edn-Lluesma","year":"2024","journal-title":"Elsevier Ltd."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0175","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.addr.2025.115713_bb0185","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.addr.2025.115713_bb0190","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","article-title":"Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in Cancer immunotherapy","volume":"23","author":"Minagawa","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115713_bb0195","series-title":"Stage-specific CAR-mediated signaling generates na\u00efve-like, TCR-null CAR T cells from induced pluripotent stem cells","volume":"28","author":"Yoo","year":"2024"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0200","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"10.1016\/j.addr.2025.115713_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112241","article-title":"Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells","volume":"42","author":"Li","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.addr.2025.115713_bb0210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","article-title":"3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115713_bb0215","series-title":"Adoptive cell therapy from the dish: potentiating induced pluripotent stem cells","author":"Lindenbergh","year":"2024"},{"key":"10.1016\/j.addr.2025.115713_bb0220","series-title":"Blood, American Society of Hematology","first-page":"4577","article-title":"Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed\/Refractory B-Cell Malignancies","author":"Mehta","year":"2022"},{"key":"10.1016\/j.addr.2025.115713_bb0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ard.2025.05.056","article-title":"Treatment of refractory systemic lupus erythematosus with off-the-shelf iPSC-derived anti-CD19 CAR T-cell therapy","volume":"84","author":"Sandhu","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2025.115713_bb0230","series-title":"Positive and Negative Selection of the T Cell Repertoire: What Thymocytes See (and don\u2019t See)","author":"Klein","year":"2014"},{"key":"10.1016\/j.addr.2025.115713_bb0235","article-title":"Role of \u03b1\u03b2 T cell depletion in prevention of graft versus host disease","author":"Abdelhakim","year":"2017","journal-title":"MDPI AG"},{"key":"10.1016\/j.addr.2025.115713_bb0240","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115713_bb0245","article-title":"Which factors influence the development of GVHD in HLA-matched or mismatched transplants?","author":"Petersdorf","year":"2017","journal-title":"Bailliere Tindall Ltd."},{"key":"10.1016\/j.addr.2025.115713_bb0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.12.006","article-title":"High frequency production of T cell-derived iPSC clones capable of generating potent cytotoxic T cells","volume":"16","author":"Nagano","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.addr.2025.115713_bb0255","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stemcr.2015.07.011","article-title":"A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy","volume":"5","author":"Ando","year":"2015","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.addr.2025.115713_bb0260","article-title":"Mini-TCRs: truncated T cell receptors to generate T cells from induced pluripotent stem cells","volume":"31","author":"Ichiro Takayanagi","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0275","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.20234","article-title":"Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: insights from a multicentre experience","volume":"207","author":"Cassanello","year":"2025","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0280","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.addr.2025.115713_bb0285","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma HHS public access","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115713_bb0290","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial a","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115713_bb0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0300","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0196-0644(85)80736-8","article-title":"Acute jaundice with renal failure","volume":"14","author":"Shields","year":"1985","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.addr.2025.115713_bb0305","series-title":"CAR-T Cell Therapy in Brain Malignancies: obstacles in the Face of Cellular Trafficking and Persistence","author":"Yaacoub","year":"2025"},{"key":"10.1016\/j.addr.2025.115713_bb0310","first-page":"1","article-title":"Enriched environment cues suggest a new strategy to counteract glioma: engineered rAAV2-IL-15 microglia modulate the tumor microenvironment","volume":"12","author":"Mormino","year":"2021","journal-title":"Article"},{"key":"10.1016\/j.addr.2025.115713_bb0315","article-title":"Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells","author":"Lund","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.addr.2025.115713_bb0320","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.immuni.2025.04.006","article-title":"Monocytes can efficiently replace all brain macrophages and fetal liver monocytes can generate bona fide SALL1+ microglia","volume":"58","author":"Bastos","year":"2025","journal-title":"Immunity"},{"issue":"6005","key":"10.1016\/j.addr.2025.115713_bb0325","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115713_bb0330","series-title":"Differentiation of Human and Murine Induced Pluripotent Stem Cells to Microglia-like Cells","author":"Pandya","year":"2017"},{"key":"10.1016\/j.addr.2025.115713_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2121-12-35","article-title":"Differentiation of mouse bone marrow derived stem cells toward microglia-like cells","volume":"12","author":"Hinze","year":"2011","journal-title":"BMC Cell Biol."},{"issue":"11","key":"10.1016\/j.addr.2025.115713_bb0340","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/nm.4189","article-title":"Efficient derivation of microglia-like cells from human pluripotent stem cells HHS public access author manuscript","volume":"22","author":"Muffat","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0345","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1038\/s41598-017-09362-3","article-title":"Excess \u03b1-synuclein compromises phagocytosis in iPSC-derived macrophages","volume":"7","author":"Haenseler","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0350","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41590-023-01558-2","article-title":"Exposure of iPSC-derived human microglia to brain substrates enables the generation and manipulation of diverse transcriptional states in vitro","volume":"24","author":"Dolan","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2025.115713_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.629279","article-title":"Validation of induced microglia-like cells (iMG cells) for future studies of brain diseases","volume":"15","author":"Banerjee","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.addr.2025.115713_bb0360","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12977-020-00544-y","article-title":"Comparative analysis of human microglial models for studies of HIV replication and pathogenesis","volume":"17","author":"Rai","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.addr.2025.115713_bb0365","article-title":"Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-alpha\/beta T cells demonstrates preferential use of several Vbeta genes and an invariant TCR alpha chain","author":"Porceui","year":"1993","journal-title":"J. Exp Med"},{"key":"10.1016\/j.addr.2025.115713_bb0370","doi-asserted-by":"crossref","DOI":"10.1084\/jem.180.3.1097","article-title":"An invariant T cell receptor \u03b1 chain is used by a unique subset of major histocompatibility complex class I-specific CD4 + and CD4-8-T cells in mice and humans","author":"Lantz","year":"1994","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0375","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0092-8674(85)90140-0","article-title":"Structure, organization, and somatic rearrangement of T cell gamma genes","volume":"40","author":"Hayday","year":"1985","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.addr.2025.115713_bb0380","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.addr.2025.115713_bb0385","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/mt.2012.267","article-title":"Bispecific T-cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T-cell receptors and introduced CD19-specific chimeric antigen receptor","volume":"21","author":"Deniger","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2025.115713_bb0390","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","author":"Li","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0395","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","article-title":"Engineering human MAIT cells with chimeric antigen receptors for Cancer immunotherapy","volume":"209","author":"Dogan","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2025.115713_bb0400","series-title":"Flow Cytometric and Immunohistochemical Characterization of the \u03b3\u03b4 T-Lymphocyte Population in Normal Human Lymphoid Tissue and Peripheral Blood","author":"lnghirami","year":"1990"},{"issue":"5","key":"10.1016\/j.addr.2025.115713_bb0405","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/eji.200425958","article-title":"Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples","volume":"35","author":"Berzins","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.addr.2025.115713_bb0410","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/imcb.12021","article-title":"Human blood MAIT cell subsets defined using MR1 tetramers","volume":"96","author":"Gherardin","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.addr.2025.115713_bb0415","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8529104","article-title":"Expansion of gammadelta T cells from cord blood: a therapeutical possibility","volume":"2018","author":"Berglund","year":"2018","journal-title":"Stem Cells Int."},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0420","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20171739","article-title":"Ontogeny of human mucosal-associated invariant T cells and related T cell subsets","volume":"215","author":"Ben Youssef","year":"2018","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.addr.2025.115713_bb0425","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/1521-4141(200006)30:6<1544::AID-IMMU1544>3.0.CO;2-I","article-title":"Neonatal invariant V\u03b124+ NKT lymphocytes are activated memory cells","volume":"30","author":"D'Andr\u00e9a","year":"2000","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-023-00275-5","article-title":"Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy","volume":"43","author":"Aoki","year":"2023","journal-title":"Inflamm Regen"},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0435","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41590-019-0578-8","article-title":"Genome-wide CRISPR\u2013Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1","volume":"21","author":"Crowther","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2025.115713_bb0440","doi-asserted-by":"crossref","DOI":"10.1084\/jem.189.12.1907","article-title":"An invariant T cell receptor \u03b1 chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted \/ T cell subpopulation in mammals","volume":"189","author":"Tilloy","year":"1999","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.addr.2025.115713_bb0445","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003123","article-title":"Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy","volume":"9","author":"Tourret","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2025.115713_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00751","article-title":"MR1-restricted T cells are unprecedented Cancer fighters","volume":"11","author":"Vacchini","year":"2020","journal-title":"Front. Immunol."},{"issue":"7149","key":"10.1016\/j.addr.2025.115713_bb0455","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nature05907","article-title":"CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor","volume":"448","author":"Borg","year":"2007","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.addr.2025.115713_bb0460","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.4049\/jimmunol.1003748","article-title":"Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-Haploidentical stem cell transplantation defines distinct CD4+ and CD4\u2212 subset dynamics and correlates with remission state","volume":"186","author":"de Lalla","year":"2011","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.addr.2025.115713_bb0465","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115713_bb0470","article-title":"AgenT-797, a novel allogenic and \u2018off-the shelf\u2019 iNKT cell therapy promotes effective tumor killing","author":"Yao","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-44905-z","article-title":"A phase 1\/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome","volume":"15","author":"Hammond","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115713_bb0480","first-page":"A305","article-title":"A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform for hematologic malignancies and solid tumors","author":"Urakami","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2025.115713_bb0485","first-page":"A358","article-title":"iPSC-derived CAR-iNKT cells targeting HER2 show prolonged tumor control and promote durable survival in a tumor xenograft model","author":"Urakami","year":"2023","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.addr.2025.115713_bb0490","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/cas.70008","article-title":"Antibody-dependent cellular cytotoxicity of iPS cell-derived natural killer T cells by anti-GD2 mAb for neuroblastoma","volume":"116","author":"Nishimura","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2025.115713_bb0495","series-title":"Cancer Research, American Association for Cancer Research","first-page":"6105","article-title":"iPSC-derived HER2 CAR-iNKT cells enhance the activity of immune cells against cancer cells","author":"Shioya","year":"2025"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0500","article-title":"\u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0505","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115713_bb0510","doi-asserted-by":"crossref","first-page":"v72","DOI":"10.1093\/neuonc\/noad179.0280","article-title":"Phase 1 study of gene modified autologous gamma-delta (\u03b3\u03b4) T cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance Temozolomide (TMZ)","volume":"25","author":"Logun","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.addr.2025.115713_bb0515","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/JCO.2024.42.16_suppl.2042","article-title":"INB-200: fully enrolled phase 1 study of gene-modified autologous gamma-delta (\u03b3\u03b4) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ)","author":"Lobbous","year":"2024","journal-title":"J. Clin Oncol, Am Society Clin. Oncol."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0520","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase 1 trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma HHS public access","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.addr.2025.115713_bb0525","series-title":"Phase I clinical trial of autologous gamma\/delta-enriched chimeric antigen receptor (CAR)-T cells to target prostate stem cell antigen (PSCA) in patients with bone metastatic prostate cancer","author":"Zhang","year":"2025"},{"key":"10.1016\/j.addr.2025.115713_bb0530","series-title":"A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma delta (\u03b3\u03b4) T Cells in Adults with B-Cell Malignancies","author":"Neelapu","year":"2022"},{"key":"10.1016\/j.addr.2025.115713_bb0535","article-title":"Induced pluripotent stem cell-derived Gamma Delta CAR-T cells for Cancer immunotherapy","author":"Wallet","year":"2021","journal-title":"Am Society Hematol"},{"key":"10.1016\/j.addr.2025.115713_bb0540","series-title":"Multiple Targeting of Solid Tumors with iPSC-Derived Gamma delta CAR T Cells in Combination with Therapeutic Antibodies","author":"Millar","year":"2022"},{"issue":"18","key":"10.1016\/j.addr.2025.115713_bb0545","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0550","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115713_bb0555","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a Meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.addr.2025.115713_bb0560","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/0277-5379(88)90069-7","article-title":"Control of the Antitumoral activity of human macrophages produced in large amounts in view of adoptive transfer","volume":"24","author":"Dumont","year":"1988","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115713_bb0565","series-title":"Adoptive Transfer of Tumor Cytotoxic Macrophages Generated In Vitro from Circulating Blood Monocytes: A New Approach to Cancer Immunotherapy","author":"Andreesen","year":"1990"},{"key":"10.1016\/j.addr.2025.115713_bb0570","series-title":"Phase I Trial of Intravenous Infusion of Ex-Vivo-Activated Autologous Blood-Derived Macrophages in Patients with Non-small-Cell Lung cancer: toxicity and Immunomodulatory Effects","author":"Faradji","year":"1991"},{"key":"10.1016\/j.addr.2025.115713_bb0575","article-title":"Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer","author":"Hennemann","year":"2025","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.addr.2025.115713_bb0580","doi-asserted-by":"crossref","DOI":"10.1097\/00002371-199204000-00008","article-title":"Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients a pilot study","author":"Lopez","year":"1992","journal-title":"J. Immunother."},{"key":"10.1016\/j.addr.2025.115713_bb0585","series-title":"Original paper phase I\/II trial of autologous activated macrophages in advanced colorectal cancer","author":"Eymard","year":"1996"},{"key":"10.1016\/j.addr.2025.115713_bb0590","article-title":"A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors","author":"Anna Reiss","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0595","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.addr.2025.115713_bb0600","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/gt.2011.22","article-title":"Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy","volume":"18","author":"Senju","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2025.115713_bb0605","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.omtn.2018.07.017","article-title":"Generation of HIV-resistant macrophages from IPSCs by using transcriptional gene silencing and promoter-targeted RNA","volume":"12","author":"Higaki","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.addr.2025.115713_bb0610","article-title":"Future prospects for cancer immunotherapy using induced pluripotent stem cell-derived dendritic cells or macrophages","author":"Fukushima","year":"2023","journal-title":"John Wiley and Sons Inc."},{"issue":"19","key":"10.1016\/j.addr.2025.115713_bb0615","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.1093\/nar\/gkt555","article-title":"Optimization of scarless human stem cell genome editing","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.addr.2025.115713_bb0620","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0625","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-024-03785-2","article-title":"Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions","volume":"15","author":"Ackermann","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"10.1016\/j.addr.2025.115713_bb0630","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/gt.2012.61","article-title":"Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein","volume":"20","author":"Bobadilla","year":"2013","journal-title":"Gene Ther."},{"issue":"13","key":"10.1016\/j.addr.2025.115713_bb0635","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1128\/JVI.00346-11","article-title":"Human immunodeficiency virus type 1 modified to package simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells","volume":"85","author":"Sunseri","year":"2011","journal-title":"J. Virol."},{"issue":"7183","key":"10.1016\/j.addr.2025.115713_bb0640","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature06664","article-title":"The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response","volume":"452","author":"Muruve","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115713_bb0645","series-title":"Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs","volume":"04","author":"Ding","year":"2013"},{"issue":"12","key":"10.1016\/j.addr.2025.115713_bb0650","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2025.115713_bb0655","series-title":"Cooperation of Immune Lymphoid Cells with Macrophages in Tumour Immunity","author":"Evans","year":"1970"},{"key":"10.1016\/j.addr.2025.115713_bb0660","article-title":"Macrophage diversity enhances tumor progression and metastasis","author":"Qian","year":"2010","journal-title":"Elsevier B.V."},{"issue":"10","key":"10.1016\/j.addr.2025.115713_bb0665","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0670","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2326-6066.CIR-21-0326","article-title":"Macrophage-targeted therapy unlocks Antitumoral cross-talk between IFNg-secreting lymphocytes and IL12-producing dendritic cells","volume":"10","author":"Pfirschke","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.addr.2025.115713_bb0675","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2025.115713_bb0680","article-title":"Macrophages as tools and targets in cancer therapy","author":"Mantovani","year":"2022","journal-title":"Nat Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0685","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.33","article-title":"Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan","volume":"7","author":"Chen","year":"2016","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.addr.2025.115713_bb0690","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.4049\/jimmunol.1402550","article-title":"NF-\u03baB regulates PD-1 expression in macrophages","volume":"194","author":"Bally","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2025.115713_bb0695","article-title":"PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","author":"Huang","year":"2009","journal-title":"PNAS"},{"issue":"5_Supplement","key":"10.1016\/j.addr.2025.115713_bb0700","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P3-06-07","article-title":"Abstract P3-06-07: phase Ib\/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer","volume":"83","author":"Davis","year":"2023","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0705","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.addr.2025.115713_bb0710","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1078-0432.CCR-21-3009","article-title":"ARRY-382 in combination with Pembrolizumab in patients with advanced solid tumors: results from a phase 1b\/2 study","volume":"28","author":"Johnson","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.addr.2025.115713_bb0715","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.addr.2025.115713_bb0720","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0725","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3727\/096368915X690279","article-title":"Safety and therapeutic potential of M2 macrophages in stroke treatment","volume":"25","author":"Chernykh","year":"2016","journal-title":"Cell Transplant."},{"issue":"10","key":"10.1016\/j.addr.2025.115713_bb0730","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","article-title":"Safety profile of autologous macrophage therapy for liver cirrhosis","volume":"25","author":"Moroni","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115713_bb0735","article-title":"Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update","author":"Kirkeby","year":"2025","journal-title":"Cell Press."},{"key":"10.1016\/j.addr.2025.115713_bb0740","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199012273232607","article-title":"Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44","author":"Fleischhauer","year":"1990","journal-title":"NEJM"},{"key":"10.1016\/j.addr.2025.115713_bb0745","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007890-199103000-00011","article-title":"Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients","volume":"51","author":"Suciu-Foca","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.addr.2025.115713_bb0750","unstructured":"A. L. Girnita, D. M. Girnita, and A. Zeevi, \u201cRole of anti-HLA antibodies in allograft rejection,\u201d in Retransplantation, vol. 12, 1997, ch. 18, pp. 151\u2013158."},{"key":"10.1016\/j.addr.2025.115713_bb0755","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13287-023-03576-1","article-title":"Generation of a bank of clinical-grade, HLA-homozygous iPSC lines with high coverage of the Spanish population","volume":"14","author":"Kuebler","year":"2023","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"10.1016\/j.addr.2025.115713_bb0760","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/stem.2865","article-title":"Repurposing the cord blood Bank for Haplobanking of HLA-homozygous iPSCs and their usefulness to multiple populations","volume":"36","author":"Lee","year":"2018","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0765","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-022-02961-6","article-title":"Public cord blood banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells","volume":"13","author":"\u00c1lvarez-Palomo","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0770","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.medj.2022.10.003","article-title":"A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population","volume":"4","author":"Yoshida","year":"2023","journal-title":"Med"},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0775","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stemcr.2023.12.003","article-title":"Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers","volume":"19","author":"Pizzato","year":"2024","journal-title":"Stem Cell Rep."},{"issue":"14","key":"10.1016\/j.addr.2025.115713_bb0780","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411810","article-title":"Hypoimmunogenic human pluripotent stem cells as a powerful tool for liver regenerative medicine","volume":"24","author":"Trionfini","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2025.115713_bb0785","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0790","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-024-03810-4","article-title":"Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity","volume":"15","author":"Tsuneyoshi","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.addr.2025.115713_bb0795","article-title":"Universal protection of allogeneic cell therapies from natural killer cells via CD300a agonism","author":"Zhang","year":"2024","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.addr.2025.115713_bb0800","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.addr.2025.115713_bb0805","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/dvg.22835","article-title":"Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells","volume":"53","author":"Tan","year":"2015","journal-title":"Genesis"},{"key":"10.1016\/j.addr.2025.115713_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.101803","article-title":"Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program","volume":"46","author":"Kanchan","year":"2020","journal-title":"Stem Cell Res."},{"issue":"4","key":"10.1016\/j.addr.2025.115713_bb0815","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","article-title":"Autologous iPSC-based vaccines elicit anti-tumor responses in vivo","volume":"22","author":"Kooreman","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7336","key":"10.1016\/j.addr.2025.115713_bb0820","first-page":"63","article-title":"Somatic coding mutations in human induced pluripotent stem cells","volume":"471","author":"Gore","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2025.115713_bb0825","article-title":"Recurrent copy number variations in human induced pluripotent stem cells","author":"Martins-Taylor","year":"2011","journal-title":"Nat Publishing Group"},{"key":"10.1016\/j.addr.2025.115713_bb0830","article-title":"Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: An important step toward ensuring safe cell therapy","author":"Movahed","year":"2025","journal-title":"Cell Press."},{"issue":"8","key":"10.1016\/j.addr.2025.115713_bb0835","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s12015-024-10783-7","article-title":"Current landscape of iPSC Haplobanks","volume":"20","author":"Escrib\u00e1","year":"2024","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0840","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-023-03612-0","article-title":"HLA-based banking of induced pluripotent stem cells in Saudi Arabia","volume":"14","author":"Alowaysi","year":"2023","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"10.1016\/j.addr.2025.115713_bb0845","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.stemcr.2023.09.001","article-title":"Creating an HLA-homozygous iPS cell bank for the Brazilian population: challenges and opportunities","volume":"18","author":"Martins de Oliveira","year":"2023","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.addr.2025.115713_bb0850","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(05)67813-0","article-title":"Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching","volume":"366","author":"Taylor","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.addr.2025.115713_bb0855","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.addr.2025.115713_bb0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2022.08.001","article-title":"A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell\u2013derived allogeneic cell therapies","volume":"25","author":"Dashnau","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2025.115713_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.101805","article-title":"GMP banking of human pluripotent stem cells: a US and UK perspective","volume":"45","author":"Abranches","year":"2020","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.addr.2025.115713_bb0870","article-title":"ISSCR guidelines for stem cell research and clinical translation: The 2021 update","author":"Lovell-Badge","year":"2021","journal-title":"Cell Press."},{"key":"10.1016\/j.addr.2025.115713_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.102036","article-title":"The global Alliance for iPSC therapies (GAiT)","volume":"49","author":"Sullivan","year":"2020","journal-title":"Stem Cell Res."},{"issue":"9","key":"10.1016\/j.addr.2025.115713_bb0880","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jcyt.2019.07.004","article-title":"Preservation of cell-based immunotherapies for clinical trials","volume":"21","author":"Li","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2025.115713_bb0885","series-title":"Best practices: Recommendations for repositories","author":"Snapes","year":"2023"},{"key":"10.1016\/j.addr.2025.115713_bb0890","unstructured":"United States Pharmacopeia, \u201cCryopreservation of Cells,\u201d 2016. [Online]. Available: https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/our-work\/biologics\/resources\/gc-1044-cryopreservation-of-cells.pdf."},{"key":"10.1016\/j.addr.2025.115713_bb0895","unstructured":"EMA, \u201cGuidelines on good manufacturing practice for advanced therapy medicinal products\u201d."},{"key":"10.1016\/j.addr.2025.115713_bb0900","series-title":"Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal\/stem cells and other common cellular therapeutics","author":"Cottle","year":"2022"},{"key":"10.1016\/j.addr.2025.115713_bb0905","series-title":"UK review and recommendations on cryopreservation of starting materials for ATMPs","author":"Advanced Therapy Treatment Centres","year":"2022"},{"issue":"10473","key":"10.1016\/j.addr.2025.115713_bb0910","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2500198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X2500198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:00:21Z","timestamp":1780549221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X2500198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":182,"alternative-id":["S0169409X2500198X"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115713","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115713"}}